Insights Into Hepatocellular Carcinoma (HCC) 2024
Perspectives on drivers in treatment decisions in the management of HCC
Northeast – April 1, 2024
Faculty Chair
Tanios Bekaii-Saab, MD
Mayo Clinic Cancer Center, Phoenix, AZ, USA
Southwest – August 7, 2024
Faculty Chair
Tanios Bekaii-Saab, MD
Mayo Clinic Cancer Center, Phoenix, AZ, USA
Central – July 12, 2023
Faculty Chair
Tanios Bekaii-Saab, MD
Mayo Clinic Cancer Center, Phoenix, AZ, USA
West – October 10, 2023
Faculty Chair
Daniel Ahn, DO
Mayo Clinic Cancer Center, Phoenix, AZ, USA
More Information
- Virtual series
- Connecticut, , Delaware, District of Columbia, Maine, Maryland, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont
More Information
- Virtual series
- Arizona, Colorado, Nevada, New Mexico, Southern California, Utah
More Information
- Virtual series
- Arkansas, , Kansas, Louisiana, Missouri, Oklahoma, Texas
More Information
- Virtual series
- West
REPORT SNAPSHOT
- A moderated roundtable discussion focusing on the treatment of HCC
- Disease state and data presentations are developed in conjunction with a national or regional oncology expert
- Insights on the following therapies will be obtained: sorafenib vs lenvatinib; checkpoint inhibitors including atezolizumab and nivolumab; and subsequent-line therapies including cabozantinib, nivolumab vs pembrolizumab, ramucirumab (high alpha-fetoprotein), regorafenib, and ipilimumab + nivolumab
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection is accomplished through use of audience response system questioning and moderated discussion
- The group of advisors comprises 10–15 medical oncologists representative of each region
